Bioclinica launches CTMS for CROs and mid-market biopharma
According to the company, the new system, OnPoint Direct, offers a “cost-friendly” pricing structure so organizations can adopt a full-featured clinical trial management solution without complex configurations and capital investment.
As Outsourcing-Pharma.com previously reported, the CTMS market is expected to reach $2bn by 2019, as CROs turn to outsourcing the technology to clinical technology providers in order to keep costs in check and in-house teams lean.
“Clinical trials are complex, and to manage this complexity large pharma and CROs use study management technology, but unfortunately enterprise implementation models and pricing tends to keep it out of reach of smaller organizations with just one or a few studies,” Ron Burns, Bioclinica's VP of Product Management, eHealth Solutions, told us.
The product was designed specifically for smaller organizations and features a rapid deployment model to decrease study setup time. The tool gives sponsors, CROs, and monitors visibility into study progress and is available to CROs for use on a study-by-study basis.
“The mid-market companies benefit greatly by having access to trial management tools without the typical implementation barriers,” explained Burns. “Often, these companies are exploring a first-time investment in a CTMS application and so cost is an important consideration.”
The system also integrates with Microsoft products such as Word, Excel, Outlook and SharePoint, which the company said is unique in the industry. “This integration provides users the ability to work in a familiar way while interacting with an enterprise application as needed,” said Burns.
